Biotechnology

Acurx Pharmaceuticals

Acurx Pharmaceuticals released FY2025 9 Months earnings on November 12 Pre-Market EST, actual revenue USD 0, actual EPS USD -5.2579

Acurx Pharmaceuticals released FY2025 Q3 earnings on November 12 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2257 (forecast USD -1.285)

Acurx Pharmaceuticals Reports Successful Phase 2 Clinical Trial Results for Antibiotic Candidate

Acurx Pharmaceuticals to Release FY2025 Q3 Earnings on November 12, Pre-Market EST, Forecast EPS: USD -1.285

Acurx Pharmaceuticals Announces New Data on Ibezapolstat

Acurx Pharmaceuticals released FY2025 Q2 earnings on August 11 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8872 (forecast USD -2.3)

Acurx Pharmaceuticals released FY2025 Semi-Annual Earnings on August 11, Pre-Market EST, with actual revenue USD 0 (forecast USD 0) and actual EPS USD -4.0081 (forecast USD -0.21)

Acurx Pharmaceuticals to Release FY2025 Q2 Earnings on August 12 Pre-Market EST, Forecast Revenue USD 0, EPS USD -0.115

Acurx Pharmaceuticals Holds Annual General Meeting Approving Multiple Proposals

Acurx Pharmaceuticals Inc. Conducts Warrant-Based Private Placement

Positive Results for Acurx's Antibiotic Ibezapolstat in Phase IIb Clinical Trials

Acurx Advances Antibiotic Candidate Ibezapolstat to Phase 3 Clinical Trials

Acurx Pharmaceuticals Inc Plans to Sell Up to 10.9 Million Shares

Acurx Pharmaceuticals Obtains New Patent for DNA Polymerase IIIC Inhibitor from Japan

Acurx Pharmaceuticals to Release Quarterly Earnings

Acurx Pharmaceuticals released FY2025 Q1 earnings on May 12 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1072 (forecast USD -0.16)

Acurx Pharmaceuticals Inc Expects Quarterly Loss of 15 Cents Per Share

Acurx Pharmaceuticals to release FY2025 Q1 earnings on May 13 Pre-Market EST, forecast EPS USD -0.16

Acurx Pharmaceuticals Announces Plan to Develop Novel Antibiotics

Acurx Pharmaceuticals Discloses Antibiotic Development Progress

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

Foxx Development

Palatin Tech

Mobile-Health Network Solutions

Nuvve

Datavault AI

CCSC Tech

Iveda Solutions

Harrison Global

Alps

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap